X

finanzen.net Amundi MSCI World ETF - weltweite Chancen, minimale Kosten

Investiere breit gestreut in über 1.300 Unternehmen aus 23 Ländern. Dank einer geringen TER* von nur 0,12% p.a. bleibt mehr von deiner Rendite dort, wo sie hingehört: in deinem Depot.

*Die Gebühren beziehen sich auf die Verwaltungsgebühren und sonstigen Verwaltungs- oder Betriebskosten des Fonds. Weitere Informationen zu allen Kosten finden Sie im Basisprospekt (KID). Hinweis: Die finanzen.net GmbH wird für die Vermarktung dieses Finanzproduktes von dritter Seite vergütet. Die Vergütung steigt mit dem Volumen der in das Finanzprodukt investierten Gelder.

Jetzt entdecken ETF-Sparplan starten

Nicht mehr anzeigen

Vertex Pharmaceuticals Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

410,90 EUR -3,30 EUR -0,80 %

16:31:38

STU

472,37 USD -5,61 USD -1,17 %

16:41:38

BTT

Vertex Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Marktkap.106,06 Mrd. EUR

KGV29,59Div. Rendite0,00%

WKN882807

ISINUS92532F1003

SymbolVRTX

Vertex Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

22.07.25PR NewswireVertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis

22.07.25PR NewswireVertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis

03.07.25PR NewswireVertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY

WerbungVertex Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

03.07.25PR NewswireVertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY

07.01.25PR NewswireOrna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

26.09.24PR NewswireVertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis

26.09.24PR NewswireVertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis

25.09.24PR NewswireHealth Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ...

25.09.24PR NewswireHealth Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ...

15.07.24PR NewswireHealth Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations

15.07.24PR NewswireHealth Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations

24.04.24PR NewswireVERTEX UND TREEFROG THERAPEUTICS GEBEN LIZENZVEREINBARUNG UND ZUSAMMENARBEIT ZUR OPTIMIERUNG DER PRODUKTION DER ZELLTHERAPIEN VON VERTEX FÜR TYP-1-DIABETES BEKANNT

23.04.24PR NewswireVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

23.04.24PR NewswireVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

23.04.24PR NewswireVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

23.04.24PR NewswireVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

01.04.24PR NewswireVertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependen...

01.04.24PR NewswireVertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependen...

17.10.23PR NewswireHealth Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation

17.10.23PR NewswireHealth Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation

29.06.23PR NewswireCanadian Investment Regulatory Organization Trade Resumption - VRTX

29.06.23PR NewswireCanadian Investment Regulatory Organization Trade Resumption - VRTX

29.06.23PR NewswireCanadian Investment Regulatory Organization Trading Halt - VRTX

29.06.23PR NewswireCanadian Investment Regulatory Organization Trading Halt - VRTX

Vertex Pharmaceuticals News

Vertex Pharmaceuticals News: auf dieser Seite finden Sie alle Vertex Pharmaceuticals News und Nachrichten zur Vertex Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vertex Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vertex Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.